Arlington Partners’s Genmab GMAB Stock Holding History

Arlington Partners’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-149	Closed	-$6K	–	531
2021 Q4	$6K	Buy	+149	New	+$6.21K	﹤0.01%	544

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arlington Partners's GMAB Position: Q1 2022 in Review

Arlington Partners sold out of Genmab (GMAB) in Q1 2022, closing a stake of 149 shares — an estimated $6K sold.

Arlington Partners first reported a position in GMAB in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 204 funds tracked by Wall St. Rank hold GMAB as of Q1 2022.

Arlington Partners reported no remaining Genmab position as of Q1 2022 after selling out during the quarter.
Arlington Partners sold 149 Genmab shares in Q1 2022, an estimated $6K.
Arlington Partners first reported a position in Genmab in Q4 2021 and held it in 1 quarter.
Arlington Partners's Genmab position peaked at $6K in Q4 2021.
204 funds tracked by Wall St. Rank held Genmab as of Q1 2022.

Based on Arlington Partners's 13F filing for Q1 2022, filed 14 Apr 2022.